Clinical trials: Transfusion-Transmitted Infections
Safety Issues
INTERCEPT Safety Evaluation on Whole Blood
The pathogen reduction system for whole blood using amustaline (S-303) and glutathione (GSH) hast a potential to decrease transfusion-transmitted infection.
- Trial name
- POINT1africa (NCT04020224)
- Testing
- Amustaline/GSH pathogen reduction technology, Standard of Care
- Sponsor
- Swiss Transfusion SRC
Anemia
INTERCEPT Safety Evaluation in Anemic Patients
The pathogen reduction (PR) system for Whole Blood (WB) using Amustaline (S-303) and Glutathione (GSH) has a potential to decrease transfusion-transmitted infection.
- Trial name
- POINT1africa (NCT03486054)
- Testing
- INTERCEPT, Standard of Care
- Sponsor
- Swiss Transfusion SRC
Malaria
Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.
- Trial name
- AIMS (NCT02118428)
- Testing
- Mirasol-treated Whole Blood, Untreated Whole Blood
- Where
- Ghana
- Volunteers
- 227 people
- Sponsor
- Terumo BCTbio